Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (HIBERIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Differing intervals for the booster dose.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Hib (Hiberix) for prophylaxis. Previously administered products included Hiberix (previously administering another brand and switched to Hiberix). On 11-JUL-2025, the patient received Hiberix. On 11-JUL-2025, an unknown time after receiving Hiberix, the patient experienced drug dose administration interval too long (Verbatim: Differing intervals for the booster dose.). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 11-JUL-2025 Other HCP reported about the administration of Hiberix's booster dose beyond the recommended interval, as they were previously administering another brand and switched to Hiberix, but were unaware of the need for an additional dose, which led to drug dose interval too long. Also asked was there any information available for the administration of Hiberix after the recommended interval. As the healthcare professional pressed on, the inquiry was escalated to global team. Also, HCP mentioned that they were not sure of how many patients were involved nor had any of their details.